PBSV

Pharma-Bio Serv, Inc.

1 filings tracked

healthcarepharmaceutical consultingMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

The investment narrative has shifted from a story of survival to one of operational optimization.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

The bear case has evolved from a focus on simple losses to a more complex critique of the company's cash conversion cycle.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every PBSV filing.

Start Free Trial

Synthesis (Verdict & Resolution)

Pharma-Bio Serv's latest filing reveals a company at a critical crossroads, attempting to transition from a legacy manufacturing entity to a lean, virtualized distributor.…

Latest Available Quarter (Q2 '26 (10-Q))

Core Takeaway

The company is operationally leaner but struggling to convert earnings to cash.

Investor Lens

A trade-off between improving operational efficiency and deteriorating cash flow quality.

Watch Next

Outcome of the PRIDCO tax grant renewal application.

Calculated Financial Trajectory (Click to filter signals)

Revenue (M)1.12

Q2 FY '25: 1.18→Q2 FY '26: 1.12

Net Income (M)0.23

Q2 FY '25: -0.20→Q2 FY '26: 0.23

Gross Margin (%)38.2%

Q2 FY '25: 39.4%→Q2 FY '26: 38.2%

Net Debt (M)-8.1

Q2 FY '25: -8.0→Q2 FY '26: -8.1

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

Signal Timeline

bullishJun 15

Company returned to operating profitability with $144.6k in operating income.

earnings beat

60%

bullishJun 15

Gross margins improved to 33.4% due to lower cost of services.

margin expansion

50%

bearishJun 15

Significant negative operating cash flow of $755k over six months.

cash burn

80%

bearishJun 15

Expiration of Puerto Rico tax grant creates potential tax liability.

regulatory action

70%

Filing History

10-QJun 15, 2026

Expand Sequence

The latest 10-Q filing for Pharma-Bio Serv presents a dichotomy between accounting profitability and cash reality. While the company has successfully reduced its overhead and flipped to a positive operating income of $144,676 for the quarter, the underlying cash flow remains negative. This suggests that while the business model is becoming more efficient on paper, the actual collection of revenue and management of working capital remain significant hurdles for the firm. Investors are left to weigh the success of the company's virtual transition and its robust asset base against the risks of high customer concentration and regulatory uncertainty in Puerto Rico. The company's ability to secure a tax grant renewal and stabilize its cash conversion cycle will be the primary determinants of whether this is a sustainable turnaround or a temporary reprieve funded by the liquidation of marketable securities.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.